Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Schizophrenia

No studies found 0 · 0%GRADE not reported 3 · 42.9%Very low 2 · 28.6%Low 2 · 28.6%Moderate 0 · 0%High 0 · 0%

Weight: clinically important change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Change in weight (kg) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 168 participants
Very low

Weight: clinically important change in BMI (kg/m2) · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Change in BMI · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 120 participants
Very low

Leaving the study early · people with schizophrenia with antipsychotic‐induced weight gain

Topiramate showed no clear difference in leaving the study early: for any reason compared with placebo or no treatment (low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.09 [0.85, 1.41]
2 studies · 132 participants
Low

Compliance with treatment · people with schizophrenia with antipsychotic‐induced weight gain

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Nausea · people with schizophrenia with antipsychotic‐induced weight gain

Topiramate showed no clear difference in reports of nausea compared with placebo or no treatment (low certainty).

1 finding from 1 review

Pharmacological interventions for prevention of weight gain in people with schizophrenia 2022 · Cochrane Headline outcomes only
RR 1.2 [0.26, 5.44]
2 studies · 120 participants
Low